Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 10/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 6/20 | 0.52 |
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10526958 | 0.82 | MPO (0.80) | MPOTAAR1SLC6A4CA12CA2 | |
| SCHEMBL2904716 | 0.78 | MPO (0.62) | MPOTAAR1SLC6A4CA12CA2 | |
| SCHEMBL1222973 | 0.78 | TAAR1 (0.71) | MPOTAAR1SLC6A4CA12CA2 | |
| SCHEMBL29706272 | 0.78 | TAAR1 (0.71) | MPOTAAR1SLC6A4CA12CA2 | |
| SCHEMBL5072950 | 0.78 | MPO (0.61) | MPOTAAR1SLC6A4CA12CA2 | |
| SCHEMBL23829545 | 0.77 | TSHR (0.67) | MPOSLC6A4CA12CA2TSHR | |
| Bromide SCHEMBL15398510 | 0.77 | MPO (0.60) | MPOTAAR1SLC6A4CA12CA2 | |
| SCHEMBL29706378 | 0.76 | TAAR1 (0.68) | MPOTAAR1SLC6A4CA12CA2 | |
| SCHEMBL25454282 | 0.75 | MPO (0.69) | MPOTAAR1SLC6A4CA12CA2 | |
| SCHEMBL4135922 | 0.75 | MPO (0.69) | MPOTAAR1SLC6A4CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389005-A1 | 7,8-DIHYDROBENZO[E]PYRIDO[3,4-C]AZOCINE-2,5(3H,6H)-DIONE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389005-A1 | 7,8-DIHYDROBENZO[E]PYRIDO[3,4-C]AZOCINE-2,5(3H,6H)-DIONE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS | F2, F13B, SERPINE1 | MPO 650/4885TAAR1 3945/4885SLC6A4 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.